Mary Dolan to Combined Modality Therapy
This is a "connection" page, showing publications Mary Dolan has written about Combined Modality Therapy.
Connection Strength
0.126
-
Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:775-786.
Score: 0.107
-
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
Score: 0.008
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
Score: 0.007
-
The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol. 1993; 32(6):477-81.
Score: 0.005